

*JW
B*
47. The method according to claim 39 further comprising an antibiotic.

*JW
B*
48. A method of treating a patient with sepsis comprising administering a composition comprising riboflavin and/or riboflavin derivative in an amount sufficient to enhance the immune function of the patient, wherein riboflavin and/or riboflavin derivative is the sole active ingredient.

*JW
B*
49. The method according to claim 48 wherein the riboflavin derivative is flavin mononucleotide, flavin adenine dinucleotide or a pharmacologically acceptable salt of riboflavin.

*JW
B*
50. The method according to claim 48 wherein the composition is administered to the patient in an amount ranging from 0.1 to 500 mg/kg of weight of the patient.

*JW
B*
51. The method according to claim 48 wherein the composition is administered to the patient in a form of intramuscular injection, intravenous injection, subcutaneous injection or oral administration.

*JW
B*
52. A method of treating a patient with sepsis comprising administering a composition comprising riboflavin monophosphate in an amount sufficient to enhance the immune function of the patient, wherein riboflavin monophosphate is the sole active ingredient.

*JW
B*
53. The method according to claim 52 wherein the composition is administered to the patient in an amount ranging from 0.1 to 500 mg/kg of weight of the patient.

*JW
B*
54. The method according to claim 52 wherein the composition is administered to the patient in a form of intramuscular injection, intravenous injection, subcutaneous injection or oral administration.

REMARKS

Claims 1-54 are pending.

Claims 1-8 issued in U.S. Patent No. 5,945,420. Claims 9-54 have been added in this preliminary amendment.

Claim 9 has been added to cover a method for treating infection by administrating to a patient in need of such treatment a composition comprising riboflavin and/or riboflavin derivative. Claims 10-18 have been added to cover specific embodiments of the method of treatment of claim 9. Support for these new claims can be found in the specification, for example, at column 2, lines 15-20 and lines 35-59; column 3, lines 23-56; column 4, lines 3-5, lines 28-39 and lines 52-66; column 5, lines 20-27; column 6, lines 8-13; and Tables 1-6 of the issued patent.

Claim 19 has been added to cover a method for treating infection by enhancing the immune function of a patient by administering to the patient a composition comprising riboflavin and/or riboflavin derivative. Claims 20-28 have been added to cover specific embodiments of the method of enhancing the immune function of claim 19. Support for these new claims can be found in the specification, for example, at column 2, lines 15-20 and lines 35-59; column 3, lines 17-56; column 4, lines 3-5, lines 28-39 and lines 52-66; column 5, lines 20-27; column 6, lines 8-13; and Tables 1-6 of the issued patent.

Claim 29 has been added to cover a method for enhancing the immune response of a host with an infection by administering to the host a composition comprising riboflavin and/or riboflavin derivative. Claims 30-38 have been added to cover specific embodiments of the method of enhancing the immune function of claim 29. Support for these new claims can be found in the specification, for example, at column 2, lines 15-20 and lines 35-59; column 3, lines 17-56; column 4, lines 3-5, lines 28-39 and lines 52-66; column 5, lines 20-27; column 6, lines 8-13; and Tables 1-6 of the issued patent.

Claim 39 has been added to cover a method of treating a patient with sepsis by administering to such a patient a sufficient amount of a composition comprising riboflavin and/or riboflavin derivative. Claims 40-47 have been added to cover specific embodiments of the method of enhancing the immune function of claim 39. Support for these new claims can be found in the specification, for example, at column 2, lines 15-20 and lines 35-59; column 3, lines 17-56; column 4, lines 3-5, lines 28-39 and lines 52-66; column 5, lines 20-27; column 6, lines 8-13; and Tables 1-6 of the issued patent.

Claim 48 has been added to cover a method of treating a patient with sepsis by administering to such a patient a composition comprising riboflavin and/or riboflavin derivative in an amount sufficient to enhance the immune function of the patient wherein riboflavin and/or riboflavin derivative is the sole active ingredient. Claims 49-51 have been added to cover specific embodiments of the method of enhancing the immune function of claim 48. Support for these new claims can be found in the specification, for example, at column 2, lines 57-59; column 3, lines 17-56; column 4, lines 52-56; column 5, lines 20-27; column 6, lines 8-13; and Tables 1 and 4 of the issued patent.

Claim 52 has been added to cover a method of treating a patient with sepsis by administering to such a patient a composition comprising riboflavin monophosphate in an amount sufficient to enhance the immune function of the patient wherein riboflavin monophosphate is the sole active ingredient. Claims 53 and 54 have been added to cover specific embodiments of the method of enhancing the immune function of claim 52. Support for these new claims can be found in the specification, for example, at column 3, lines 25-31 and lines 45-57; column 4, lines 52-56; column 5, lines 20-27; column 6, lines 8-13; and Tables 1 and 4-7 of the issued patent.

None of the above new claims adds any new matter.

CONCLUSION

Applicant encloses herewith a reissue application fee transmittal form indicating the fee to be paid for this Application.

No additional fees are believed to be due in connection with this communication. However, please apply any additional charges, or credit any overpayment, to our Deposit Account No. 08-0219.

Respectfully submitted,



Hollie L. Baker
Registration No. 31,321

Date: August 30, 2001
HALE AND DORR LLP
60 State Street
Boston, MA 02109
Telephone: 617-526-6110